Insilico and SK Biopharmaceuticals sign AI drug discovery deal (opens in new tab)

Insilico and SK Biopharmaceuticals have agreed a research and development collaboration, announced at BIO 2026, to discover AI-enabled drug candidates for neuroimmune disorders of the central nervous system. Under the deal, Insilico will use its Pharma.AI platform for target validation, generative chemistry and molecule optimization and provide preclinical discovery expertise, while SK Biopharmaceuticals will lead […] The post appeared first on <a href="